Uscom Limited
UCM.AX
Australian Securities Exchange0.01
AUD
+0.00
- -
Uscom Limited
UCM.AX
(Australian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices. Its core products include the USCOM 1A advanced hemodynamic monitor, which uses Doppler ultrasound to measure cardiovascular function, detect abnormalities, and guide treatments, primarily in pediatric, emergency, intensive care, and anesthesia settings; the Uscom BP+ central blood pressure monitor that provides supra-systolic oscillometric measurement of central and peripheral blood pressure waveforms; and the Uscom SpiroSonic digital ultrasonic spirometers, which are high-fidelity pulmonary function testing devices based on multi-path ultrasound technology with wireless interfacing for remote tele-monitoring of pulmonary diseases. The company also offers proprietary software platforms such as SpiroReporter for data management and analysis. Uscom operates globally, with key markets including Australia, Asia, the Americas, and particularly China, which remains its largest revenue source. The company was founded in 2000, headquartered in Sydney, Australia, and has grown through strategic acquisitions including Pulsecor Limited in 2013 and Thor Laboratories in 2015, enhancing its portfolio of non-invasive cardiovascular and pulmonary technologies. In recent developments, Uscom Limited entered in 2025 into an agreement to sell its business and assets, including its wholly-owned subsidiary Uscom Sng Pte. Ltd, to Singapore-based AXO Medtech VCC for approximately AUD 2.59 million. This strategic sale, subject to shareholder approval, aims to secure capital needed to accelerate global expansion and operational development after prolonged financial losses and difficulty raising funds locally. AXO Medtech plans to maintain Uscom’s current operations, subsidiaries, employee base, and IP, focusing on expanding the clinical and technical support teams, especially in the US market, to leverage new partnerships, including a significant recent distribution alliance with SinoPharm in China and a strategic partnership with a leading US hospital group purchasing organization. Uscom continues to develop new product iterations and digital technologies to complement and upgrade its existing devices, aiming to reinforce its position in cardiovascular and pulmonary monitoring worldwide. Uscom’s business segments include advanced hemodynamic monitoring, central blood pressure measurement, and pulmonary function testing devices, targeting hospital, clinical, and remote patient monitoring markets. Its technology platform revolves around non-invasive ultrasound and oscillometric techniques that replace invasive procedures traditionally used in cardiac and pulmonary diagnostics. The company maintains a strong research pipeline supported by extensive IP protection with patents in China and other territories, positioning it for continued innovation in medical technology devices. It employs around 35 staff and focuses on creating clinically beneficial products that improve patient outcomes and healthcare delivery globally. Uscom Limited remains an influential player in the medical technology industry specializing in non-invasive diagnostics, with a comprehensive product suite addressing cardiovascular and pulmonary health, supported by recent strategic moves designed to stabilize its finances and accelerate growth under new ownership and partnerships.